Who are ANA598's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rosiglitazone and Pegasys/Ribavirin, sofosbuvir/ledipasvir, sofosbubir/velpatasvir, OBV/PTV/r and DSV, ABT450r-ABT267-ABT333 +/- Ribavirin, Sofosbuvir + Simeprevir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ana598.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ANA598 — Competitive Intelligence Brief

ANA598 (ANA598) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NS5B polymerase inhibitor. Area: Infectious Diseases.

phase 2 NS5B polymerase inhibitor NS5B polymerase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

ANA598 (ANA598) — Hoffmann-La Roche. ANA598 is a non-nucleoside inhibitor of the NS5B polymerase of the hepatitis C virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ANA598 TARGET	ANA598	Hoffmann-La Roche	phase 2	NS5B polymerase inhibitor	NS5B polymerase
Rosiglitazone and Pegasys/Ribavirin	Rosiglitazone and Pegasys/Ribavirin	Beth Israel Medical Center	marketed	Thiazolidinedione (rosiglitazone) combined with pegylated interferon alfa-2a and nucleoside analog (ribavirin)	PPAR-γ (rosiglitazone); Interferon-α receptor and HCV NS5B polymerase (pegasys/ribavirin)
sofosbuvir/ledipasvir	sofosbuvir/ledipasvir	University of Texas Southwestern Medical Center	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase and NS5A protein
sofosbubir/velpatasvir	sofosbubir/velpatasvir	Partners in Health	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase and NS5A protein
OBV/PTV/r and DSV	OBV/PTV/r and DSV	Hannover Medical School	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS3/4A protease, NS5B polymerase
ABT450r-ABT267-ABT333 +/- Ribavirin	ABT450r-ABT267-ABT333 +/- Ribavirin	Ottawa Hospital Research Institute	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease, NS5A protein, NS5B polymerase
Sofosbuvir + Simeprevir	Sofosbuvir + Simeprevir	University of California, San Francisco	marketed	Antiviral combination (nucleotide polymerase inhibitor + protease inhibitor)	HCV NS5B polymerase and NS3/4A protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NS5B polymerase inhibitor class)

Bristol-Myers Squibb · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ANA598 — Competitive Intelligence Brief. https://druglandscape.com/ci/ana598. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab